Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Antibody-drug conjugates hitting this target abound.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
